Anti-BCMA and T Cell Engager Combination for Relapse and Ocular Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma and other cancers, such as monoclonal antibodies, often lead to relapse and have significant side effects, necessitating the development of alternative or improved compositions and methods for more effective cancer therapy.
Innovation Solution
Combining anti-BCMA antigen binding proteins, such as belantamab mafodotin, with T cell engagers like Cevostamab, to enhance cancer treatment efficacy and reduce side effects, particularly ocular toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies or single-agent therapies are used to treat multiple myeloma, then initial treatment response is achieved, but relapse occurs and side effects accumulate
Solution Approach 1:
The patent combines multiple therapeutic agents with different mechanisms of action (anti-BCMA antibody, T cell engager, and potentially other agents) into a combination therapy regimen. This merging of therapies allows simultaneous targeting of multiple pathways, achieving both immediate response and sustained control to prevent relapse, thereby resolving the contradiction between initial efficacy and duration of response.
2Productivity
If higher doses of single agents are administered to improve treatment efficacy, then anticancer activity increases, but side effects particularly ocular toxicity worsen
Solution Approach 1:
The patent segments the anticancer activity into multiple distinct therapeutic agents, each administered at lower, better-tolerated doses rather than one high-dose agent. The T cell engager and anti-BCMA antibody work through different mechanisms, allowing the regimen to achieve high overall efficacy while distributing and reducing the toxic burden on specific organs, particularly the eyes.
Solution Approach 2:
The patent changes the dosing parameters by administering multiple agents at lower individual doses compared to single high-dose therapy. This parameter change in dosing strategy maintains or enhances anticancer activity while reducing the peak toxic effects, particularly ocular toxicity associated with higher doses of single agents.
3Reliability
If combination therapies are used to enhance efficacy, then treatment effectiveness improves, but treatment complexity increases
Solution Approach 1:
The patent employs a combination regimen where each agent serves multiple functions: the anti-BCMA antibody provides targeted cytotoxicity, the T cell engager activates immune response, and together they create synergistic effects. This multi-functionality approach achieves enhanced effectiveness while the standardized combination protocol manages complexity through established dosing schedules and administration routes.
Data Source
AI summary
Disclosed herein are methods and materials for treating cancer. The disclosure further provides methods and materials for using one or more antigen binding proteins (for example anti-B-cell maturation antigen (BCMA) antigen binding proteins) and one or more T cell engagers for treating a subject having cancer.